Sign in
TerminatedPhase 4

Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients

Key facts

Who runs it
Korea University Guro Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
25 people enrolled
Started
15 Jun 2023
Ended
23 Jan 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Acetaminophen and Ibuprofen
  • Normal saline
Record updated
5 September 2025
Why it stopped
The study was terminated early owing to challenges in completing the research registration process.

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients aged 65 years or older undergoing minimally invasive lung lobectomy or segmentectomy

Who cannot take part

  • Anticoagulants or antiplatelet agents are maintained for up to 5 days before surgery
  • Hypersensitivity to the main ingredients and additives of Maxigesic
  • Hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Bleeding tendency (e.g., Spontaneous bleeding)
  • Uncontrolled hypertension(HTN) (Systolic blood pressure >180 mmHg)
  • High-dose methotrexate (MTX) for cancer treatment
  • Preoperative cognitive impairment, dementia, or delirium
  • Severe hepatic dysfunction (AST, AST ≥2.5 * upper normal limit(UNL) or Total bilirubin ≥3.0 mg/dl)
  • Severe renal dysfunction (eGFR <30 ml/min/1.73m2 or Dialysis)
  • Severe heart failure (Left ventricle ejection fraction <30%)
  • Alcoholism / Alcohol intoxication
  • Severe hematological abnormalities
  • Symptomatic asthma in need of treatment
  • Barbiturates or tricyclic antidepressants (TCAs)
  • Inability to understand the research and instructions for this study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary aim of this interventional study is to investigate the impact of perioperative administration of Maxigesic (combination of acetaminophen and ibuprofen) on delirium after minimally invasive lung surgery in elderly patients. The Maxigesic group receives a total of 5 doses of Maxigesic (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthesia induction. The control group receives the same volume of normal saline. Researchers compare the incidence and severity of postoperative delirium for 5 days after surgery.

The 2 groups in the trial

  • Maxigesic groupTreatment being tested

    Treatment: Acetaminophen and Ibuprofen

  • Control groupPlacebo, for comparison

    Treatment: Normal saline

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact of Intravenous Administration of Perioperative Acetaminophen and Ibuprofen Combination (Maxigesic®) on Postoperative Delirium in Elderly Patients Undergoing Minimally Invasive Lung Segmentectomy or Lobectomy
Record updated
5 September 2025